RuiShou Pet Completes Tens of Millions RMB Angel Financing to Advance Commercialization of Scientific Pet Breeding

VCBeat has learned that Huangshan Ruishou Pet Service Co., Ltd. (hereinafter referred to as “Ruishou Pet”) announced today the completion of an angel financing round worth tens of millions of yuan, with investment participation from Huangshan District Agricultural, Cultural, and Tourism Development Co., Ltd. The proceeds will be primarily allocated to the research and development and application of embryo engineering technologies, the upgrade of a platform for screening and preventing genetic defects in pets based on single-cell amplification technology, the expansion of its service network, and the optimization of its supply chain system.

Through these investments, the company aims to achieve precise and efficient breeding of rare pets and build a pet brand grounded in healthy genetics. Established in 2024, Ruishou Pets is committed to its mission and vision of “enabling every pet to enjoy healthier, longer companionship,” positioning itself as a provider of holistic health management services across the entire pet life cycle.

“Pet consumption is undergoing a profound transformation from basic survival needs to health and quality,” emphasized Wei Tao, founder of Ruishou Pet. “Addressing genetic defects within breeds, safeguarding pets’ lifelong health, and meeting market demand for rare, high-quality pets represent the core pain points and opportunities in the industry today. We are building a dual-engine-driven solution centered on embryonic engineering and gene technology.”

According to the "2025 White Paper on China's Pet Industry," the number of pet dogs and cats in urban areas of China reached 120 million in 2024. In recent years, China’s pet reproductive services industry has experienced rapid growth, with its market size continuously expanding. The "Research Report on Development Trends and Investment Risks of China's Pet Medical Industry (2025–2030)" indicates that the market size of China's pet medical industry reached RMB 94 billion in 2024, a year-on-year increase of 14.49%. As an important component of the pet medical market, the pet reproductive services industry is gaining increasing attention, evolving from traditional pet breeding services to comprehensive offerings that include genetic counseling, prenatal examinations, and delivery care.

Amid the consumption upgrade driven by the “humanization” of pets, high-net-worth individuals demonstrate a strong willingness to pay for scientific breeding services, accelerating the penetration of premium offerings such as genetic screening and eugenic breeding. As post-90s and post-00s generations become the primary pet owners, the role of pets has evolved from “companions” to “family members,” leading to an exponential increase in consumer demand for pet health, purebred lineage, and long-term quality of life. This trend is propelling “scientific breeding” to emerge as the third high-potential sector, following pet food and veterinary care.

Ruishou Pet has entered into a strategic partnership with Yikon Genomics, a global leader in assisted reproductive technology. The two parties will jointly promote the translation and application of MALBAC® single-cell whole-genome amplification technology—a human assisted reproductive technology—into the field of healthy pet breeding. By leveraging precise genetic screening to reshape industry standards for pet breeding, they aim to lead the market into a blue-ocean sector valued at hundreds of billions.

Technical Application:Introduce and optimize advanced embryo engineering technologies, including in vitro embryo culture, embryo transfer, and embryo cryopreservation (for the establishment of germplasm resource banks).

Target Value:Achieve efficient and precise propagation of market-scarce, high-value pet breeds (such as specific lineage show-grade dogs and cats, and rare pets), significantly shortening the breeding cycle for superior bloodlines and enhancing the efficiency and controllability of population reproduction.

Commercial Potential:To meet the robust demand in the high-end market for rare, premium-quality pets, thereby creating core competitiveness and greater commercial value for partner breeding institutions.

Reducing the Risk of Genetic Defects:Leveraging technologies such as MALBAC® single-cell whole-genome amplification, we conduct high-throughput, precise screening for over 200 common hereditary diseases in dogs and cats, including feline hypertrophic cardiomyopathy (HCM) and canine multifocal retinopathy. Our goal is to reduce the incidence of common hereditary diseases in offspring bred by partner institutions by 80% within three years, fundamentally raising the health baseline of pet populations.

Health Breeding Standards:Provide scientific breeding pair guidance based on genetic screening results, block the transmission of disease-causing genes at the source, and promote the establishment of new “healthy gene” standards in the industry.

“Health Certification” Brand:Issue the “Ruishou Healthy Gene Certification” to pets that have passed rigorous genetic disease screening, build a pet brand image centered on “health and longevity,” and enhance consumer trust and premium pricing power.

Molecular ID and Blockchain: Each pet’s genetic data generates a unique “molecular ID,” which is recorded on the blockchain for verification and shared with authoritative associations to ensure authentic and transparent pedigrees, thereby eliminating fraud and the risk of inbreeding.

This collaboration represents a strategic initiative by Ruishou Pet to build a preventive healthcare ecosystem. Diverging from the traditional “one-off transaction” model, Ruishou Pet integrates MALBAC® technology into its full-lifecycle management system covering “breeding, medical care, insurance, and elderly pet care,” thereby creating a sustainable commercial loop for monetization. The company will provide genetic pairing services to breeding institutions, offer hereditary disease screening packages to individual consumers, and develop customized insurance and nutritional plans leveraging its genetic database. Furthermore, subject to legal and regulatory compliance, Ruishou Pet plans to enter the pet cloning market to meet demands for emotional continuity.

Wei Tao, Founder of Ruishou PetsHe stated, “Pet breeding has transitioned from a phase of ‘quantity expansion’ into a new era defined by a ‘quality revolution and health-first approach.’ We leverage embryo engineering technologies to safeguard rare bloodlines, while employing genetic technologies to provide pets with a healthy start in life. This is not merely a commercial endeavor; it represents an upgrade in industry ethics. When pets are regarded as family members, we have a responsibility to scientifically maximize their health and longevity. Ruishou’s goal is to ensure that ‘embryo engineering’ serves population conservation and diversity, and to make ‘genetic screening’ a standard practice in scientific breeding—as essential and widespread as prenatal checkups for humans.”